Отправить статью
EN
Адрес для писем
220006, г. Минск, ул. Ленинградская 6, кабинет 2
Телефон: +375 17 363-88-92
Эл.почта: medjournal@bsmu.by
  • Главная
  • Выпуски
  • 2021 №2
  • Перспективы использования лигандов и их рецепторов в крови для диагностики немелкоклеточного рака лёгкого

Перспективы использования лигандов и их рецепторов в крови для диагностики немелкоклеточного рака лёгкого

Д. И. Мурашко, А. Д. Таганович УО «Белорусский государственный медицинский университет»
2021 №2 | Лекции
Аннотация
Список литературы
Скачать полнотекстовую статью
Рак лёгкого – одно из наиболее распространённых злокачественных новообразований. Большая часть в структуре заболеваемости принадлежит немелкоклеточному раку легкого (НМРЛ). Прогноз выживаемости при данном заболевании в значительной степени зависит от стадии заболевания на момент первого выявления. В настоящее время для диагностики данного заболевания преимущественно используются компьютерная томография и гистологическое исследование опухолевой ткани. Однако эти методы требуют особого технического оснащения и высокой квалификации специалистов. По этой причине ранняя диагностика заболевания затруднена. Это побуждает к поиску доступных и информативных биохимических показателей, имеющих патогенетическую значимость, которые позволили бы судить о наличии и степени распространенности злокачественного процесса уже на ранних стадиях заболевания. Цель работы - обосновать целесообразность экспериментального изучения рецепторов иммунокомпетентных клеток и их лигандов как потенциальных биомаркеров для диагностики немелкоклеточного рака лёгкого.
Ключевые слова:
немелкоклеточный рак легкого, хемокины, рецепторы, ранняя диагностика
The possibility of using ligands and their recrptors in the blood for the diagnosis of non-small cell lung cancer

Lung cancer is one of the most common malignant neoplasms. Most of the morbidity structure belongs to non-small cell lung cancer. (NSCLC). The prognosis of survival for a given disease depends on the stage of the disease at the time of the first condition. Currently, computed tomography and histological examination of tumor tissue are mainly used to diagnose this disease. However, these methods require special technical equipment and highly qualified specialists. For this reason, early diagnosis of the disease is difficult. This prompts the search for available and informative biochemical parameters that have pathogenetic significance, which would make it possible to judge the presence and extent of the malignant process already in the early stages of the disease. The aim of this work is to substantiate the feasibility of experimental study of receptors of immunocompetent cells and their ligands as potential biomarkers for the diagnosis of non-small cell lung cancer.

Keywords
non-small cell lung cancer, chemokines, receptors, early diagnosis
  • 1. Cancer, Lung [Updated 2020 Jul 17] [Электронный ресурс] / StatPearls Publishing. – Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK482357/
  • 2. Molecular pathogenesis of early­stage non­small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers / Maria Gabriela Raso // Journal of Thoracic Oncology. – 2007. – Vol. 2, №7. – P. 128–135.
  • 3. Early-stage and locally advanced (non­metastatic) nonsmall cell lung cancer. ESMO Clinical Practise Guidelines for diagnosis? Treatment and follow­up / L. Crino [et al.] // Annals of Oncology. – 2010. – Vol. 21, № 5. – P. 103–115.
  • 4. Lung cancer staging and prognosis / Gavitt A Woodard [et al.] // The Cancer Treat Res. – 2016. – Vol. 170. – Р. 47–75.
  • 5. Survival of patients with stage I lung cancer detected on CT screening / Internatrional Early Lung Cancer Action Program Investigators [et al.] // N Engl J Med. – 2006. – Vol. 355, № 17. – Р. 1763–1771.
  • 6. Non-small cell lung cancer: epidemiology, screening, diagnosis and treatment / Narjust Duma [et al.] // Mayo Clin Proc. – 2019. – Vol. 94, № 8. – Р. 1623–1640.
  • 7. Triple test tumor marker with CYFRA 21–1, HE4 and ProGRP might contribute to diagnosis and subtyping of lung cancer / Elif T. Korkmaz [et al.] // Clin Biochem. – 2018. – Vol. 58. – Р. 15–19.
  • 8. CYFRA 21-1 cytosol levels in lung adenocarcinomas. Correlation with other clinico­biological parameters / A. Ruibal [et al.] // Rev Esp Med Nucl. – 2002. – Vol. 21, № 5. – P. 333–337.
  • 9. Diagnostic value of CYFRA 21–1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease / Feng Chen [et al.] // J Cancer Res Ter. – 2018. – Supplement. – P. 400­ 404.
  • 10. A comparsion of serum CYFRA 21–1 and SCC Ag in the diagnosis of squamous cell lung carcinoma / Y. S. Kim [et al.] // Corean J Intern Med. – 1996. – Vol. 11, № 1. – Р. 50–57.
  • 11. Cancer-related inflammation and treatment effectiveness / Diakos CI [et al.] //Lancet Oncol. – 2014. – Vol. 15, № 11. – Р. 493–503.
  • 12. CXC chemokines in cancer, angiogenesis and metastases / E. S. Keeley [et al.] //Adv Cancer Res. – 2010. – Vol. 106. – Р. 91–111.
  • 13. Chemokines in angiogenesis / Anna Dimberg // Curr Top Microbiol Immunol. – 2010. – Vol. 341. – P. 59 – 80.
  • 14. Chemokine control of lymphocyte trafficking: a general overview / Jens V. Stein [et al.] // Immunology. – 2005. – Vol. 116, № 1. – P. 1–12.
  • 15. Role of the CXCL8­CXCR1/2 Axis in Cancer and Inflammatory Diseases / H. Ha, B. Debnath, N. Neamati // Theranostics. – 2017. – Vol. 7, № 6. – P. 1543–1588.
  • 16. The IL-8/CXCR1 axis is associated with cancer stem cell­like properties and correlates with clinical prognosis in human pancreatic cancer cases / Lianyu Chen [et al.] // Nature. – 2014. – Sci Rep 4, 5911.
  • 17. The clinical significance of CXCL5 in non­small cell lung cancer / Kongju Wu [et al.] // Onco Targets Ther. – 2017. – Vol. 10. – P. 5561–5573.
  • 18. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF­κB pathway in colorectal cancer / Chun Chen [et al.] // Nature. – 2019. – Cell Death Dis 10, 178.
  • 19. Serum chemokine CXCL8 as a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C­reactive protein, and classic tumor markers CA 19­9 and CEA / Ala Litman­Zawadzka [et al.] // Polish Archive of Internal Medicine. – 2018. – Vol. 128, № 9. – P. 524–531.
  • 20. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis / Ruiling Yan [et al.] // Biosci Rep. – 2017. – Vol. 37, № 6. –BSR20171021.
  • 21. Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer / Huijuan Bi [et al.] // Oncol Lett. – 2019. – Vol. 18, № 4. – P. 4176–4184.
  • 22. Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma / Yan Liu [et al.] // Oncol Lett. ­ Vol. 10, № 3. – P. 1315–1322.
  • 23. Diagnostic Value of Circulating CXC Chemokines in Non­small Cell Lung Cancer / A. Sparks [et al.] // Anticancer Res. – 2015. – Vol. 35, № 12. – P. 6979–6983.
  • 24. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo­adjuvant chemotherapy in breast cancer / Miao­Qun Xue [et al.] // Oncotarget. – 2017. – Vol. 8, № 30. – P. 48930–48937.
  • 25. Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer / Jingkun Zhao [et al.] // Oncotarget. – 2017. – Vol. 8, № 17. – p. 28442–28454.
  • 26. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target / Wen Zhang [et al.] // Cancer Commun. – 2020. – Vol. 40, № 2–3. – P. 69–80.
  • 27. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells / L. T. Senbanjo [et al.] // Frontiers in Cell and Developmental Biology. – 2017. – Vol. 5, № 18.
  • 28. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non­small cell lung cancer /T. Miyoshi [et al.] // Clin Cancer Res. – 1997. ­ Vol. 3, № 8. – P. 1289–1297.
  • 29. Expression and significance of E­cadherin, CD44v6, and proliferating cell nuclear antigen in non­small cell lung cancer / Mi­Xia Weng [et al.] // Chinese journal of cancer. – 2008. – Vol. 27, № 2. – P. 191–195.
  • 30. MMP­2, TIMP­2 and CD44v6 expression in non­small­cell lung carcinomas / Bulent Eren [et al.] // Ann Acad Med Singap. – 2008. – Vol.37, № 1. – P. 32–39.
  • References
  • 1. Cancer, Lung [Updated 2020 Jul 17] [Electronic resource] / StatPearls Publish­ing // Access mode: https://www.ncbi.nlm.nih.gov/books/NBK482357/
  • 2. Molecular pathogenesis of early­stage non­small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers / Maria Gabriela Raso // Journal of Thoracic Oncology. – 2007. – Vol. 2, № 7. – P. 128–135.
  • 3. Early-stage and locally advanced (non­metastatic) nonsmall cell lung cancer. ESMO Clinical Practise Guidelines for diagnosis? Treatment and follow­up / L. Crino [et al.] //Annals of Oncology. – 2010. – Vol. 21, № 5. – P. 103–115.
  • 4. Lung cancer staging and prognosis / Gavitt A Woodard [et al.] // The Cancer Treat Res. – 2016. – Vol. 170. – Р. 47–75.
  • 5. Survival of patients with stage I lung cancer detected on CT screening. / Interna­trional Early Lung Cancer Action Program Investigators [et al.] // N Engl J Med. – 2006. – Vol. 355, № 17. – Р. 1763–1771.
  • 6. Non-small cell lung cancer: epidemiology, screening, diagnosis and treatment. / Narjust Duma [et al.] // Mayo Clin Proc. – 2019. – Vol. 94, № 8. – P. 1623–1640.
  • 7. Triple test tumor marker with CYFRA 21–1, HE4 and ProGRP might contribute to diagnosis and subtyping of lung cancer / Elif T Korkmaz [et al.] // Clin Bio­chem. – 2018. – Vol. 58. – Р. 15–19.
  • 8. CYFRA 21-1 cytosol levels in lung adenocarcinomas. Correlation with other clinico­biological parameters / A. Ruibal [et al.] // Rev Esp Med Nucl. – 2002. – Vol. 21, № 5. –P. 333–337.
  • 9. Diagnostic value of CYFRA 21–1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease / Feng Chen [et al.] // J Cancer Res Ter. – 2018. – Supplement. – P. 400–404.
  • 10. A comparsion of serum CYFRA 21–1 and SCC Ag in the diagnosis of squamous cell lung carcinoma / Y. S. Kim [et al.] // Corean J Intern Med. – 1996. – Vol. 11, № 1. –Р. 50–57.
  • 11. Cancer-related inflammation and treatment effectiveness / CI. Diakos [et al.] // Lancet Oncol. – 2014. – Vol. 15, № 11. – Р. 493–503.
  • 12. CXC chemokines in cancer, angiogenesis and metastases / E. S. Keeley [et al.] // Adv Cancer Res. – 2010. – Vol. 106. – Р. 91–111.
  • 13. Chemokines in angiogenesis / Anna Dimberg // Curr Top Microbiol Immunol. – 2010. – Vol. 341. – P. 59–80.
  • 14. Chemokine control of lymphocyte trafficking: a general overview / Jens V. Stein [et al.] // Immunology. – 2005. – Vol. 116, № 1. – P. 1–12.
  • 15. Role of the CXCL8­CXCR1/2 Axis in Cancer and Inflammatory Diseases / H. Ha, B. Debnath, N. Neamati // Theranostics. – 2017. – Vol. 7, № 6. – P. 1543–1588.
  • 16. The IL-8/CXCR1 axis is associated with cancer stem cell­like properties and correlates with clinical prognosis in human pancreatic cancer cases / Lianyu Chen [et al.] // Nature. – 2014. – Sci Rep 4, 5911.
  • 17. The clinical significance of CXCL5 in non­small celllung cancer / Kongju Wu [et al.] // Onco Targets Ther. – 2017. – Vol. 10. – P. 5561–5573.
  • 18. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF­κB pathway in colorectal cancer / Chun Chen [et al.] // Nature. – 2019. – Cell Death Dis 10, 178.
  • 19. Serum chemokine CXCL8 as a better biomarker for diagnosis and predic­tion of pancreatic cancer than its specific receptor CXCR2, C­reactive protein, and classic tumor markers CA 19­9 and CEA / Ala Litman­Zawadzka [et al.] // Polish Archive of Internal Medicine. – 2018. – Vol. 128, № 9. – P. 524–531.
  • 20. The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis / Ruiling Yan [et al.] // Biosci Rep. – 2017. – Vol. 37, № 6. – BSR20171021.
  • 21. Interleukin-8 promotes cell migration via CXCR1 and CXCR2 in liver cancer / Huijuan Bi [et al.] // Oncol Lett. – 2019. – Vol. 18, № 4. – P. 4176–4184.
  • 22. Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma / Yan Liu [et al.] // Oncol Lett. ­ Vol. 10, № 3. – P. 1315–1322.
  • 23. Diagnostic Value of Circulating CXC Chemokines in Non-small Cell Lung Cancer / A. Sparks [et al.] // Anticancer Res. – 2015. – Vol. 35, № 12. – P. 6979–6983.
  • 24. Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo­adjuvant chemotherapy in breast cancer / Miao­Qun Xue [et al.] // Oncotarget. – 2017. – Vol. 8, № 30. – P. 48930–48937.
  • 25. Overexpression of CXCR2 predicts poor prognosis in patients with colo­rectal cancer / Jingkun Zhao [et al.] // Oncotarget. – 2017. – Vol. 8, № 17. – P. 28442–28454.
  • 26. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target / Wen Zhang [et al.] // Cancer Commun. – 2020. – Vol. 40, № 2–3. –P. 69–80.
  • 27. CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells / L. T. Senbanjo [et al.] // Frontiers in Cell and Developmental Biology. – 2017. – Vol. 5, № 18.
  • 28. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non­small cell lung cancer /T. Miyoshi [et al.] // Clin Cancer Res. – 1997. ­ Vol. 3, № 8. – P. 1289–1297.
  • 29. Expression and significance of E­cadherin, CD44v6, and proliferating cell nuclear antigen in non­small cell lung cancer / Mi­Xia Weng [et al.] // Chinese journal of cancer. – 2008. – Vol. 27, № 2. – P. 191–195.
  • 30. MMP-2, TIMP­2 and CD44v6 expression in non­smallcell lung carcino­mas / Bulent Eren [et al.] // Ann Acad Med Singap. – 2008. – Vol. 37, № 1. – P. 32–39.